drugset / Trial / NCT07317440
Coenzyme Q10 in Pediatric Community-Acquired Pneumonia
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
Timeline
- Start
- 2025-12-31
- Primary completion
- 2026-06-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 100 mg/kg | Oral |
| Subject | Coenzyme Q10 | Other / unclassified | 200 mg/kg | Oral |
Indications
No indication recorded.